Oct 7 2009
The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce the full agenda for the upcoming Biotech/Pharma Finance and Accounting Forum in San Francisco on November 19, 2009. Marc J. Fagel, Regional Director of the San Francisco Regional Office at the U.S. Securities and Exchange Commission, is the most recent addition to the program's elite faculty and will address SEC enforcement and the review process.
This comprehensive one-day forum delves into the accounting and biotech financial reporting issues that matter most during these tough economic times and, in addition to the SEC, will include presentations from firms such as Cell Genesys, Affymax, BioMarin Pharmaceuticals, Monogram Biosciences, Inc., Oncomed and Poniard Pharmaceuticals. Over 2,400 executives have attended CBI's Pharmaceutical Accounting and Financial Reporting Congress since its inception more than five years ago, and this year's San Francisco program has been specifically designed for innovative life science companies.
Other opportune session topics include:
- Taking the Pulse on the Economy and Chief Financial Challenges/Opportunities for Today's Biotech Companies
- Wall Street Address: Creating Value and Securing Capital for Life Science Companies in a Strained Economy
- Collaborative R&D Deals, Revenue Recognition and Accounting for Multiple Arrangements - Update on EITFs 08-1, 08-9 and 00-21
- CFO Strategies and Capital Raising in a Tough Economy
Source:
The Center for Business Intelligence
Closing the Cancer Care Gap with the Power of Precision Oncology